EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II–III Malignant Melanoma

Vlad Alexandru Gâta iD, Daniel Corneliu Leucuța iD, Radu Alexandru Ilieș, Ștefan Țîțu iD, Ana Maria Mureșan-Bădescu iD, Delia Nicoară, Ioan Constantin Pop iD, Alex Victor Orădan iD, Maximilian Vlad Muntean, Anda Gâta iD

International Journal of Molecular Sciences · 09.07.2026 · 27 (14) · 6150

DOI: 10.3390/ijms27146150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.07.2026. Verfasst von Vlad Alexandru Gâta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncological Surgery and Gynecological Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, Mutation, Skin Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iuliu Hațieganu University of Medicine and Pharmacy, “Iuliu Hațieganu” University of Medicine and Pharmacy Cluj-Napoca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with advanced or metastatic melanoma, BRAF mutation assessment is routinely performed to identify patients who may benefit from BRAF-targeted therapy. This study aimed to assess the role of BRAF mutation status in relation to histopathological characteristics and survival of patients with stage II and III malignant melanoma. A prospective cohort of 108 patients with pT3 malignant melanoma who were treated in a comprehensive cancer center were included in the analysis. All patients were treated according to contemporary melanoma management guidelines between 2016 and 2024, with a minimum follow-up of 12 months extending to 2025. Overall survival (OS) and progression-free survival (PFS) analyses were performed in the study cohort. The study included 108 patients with stage II–III malignant melanoma, with a mean age of 56.73 ± 13.51 years. Superficial spreading melanoma was the most frequent histological subtype, followed by nodular and acral melanoma. Most tumors were classified as Clark level IV, with a median Breslow thickness of 3 mm, and ulceration was present in the majority of cases. Lymph node involvement was observed in over half of the patients, and BRAF mutations were identified in 56.48% of cases (the most common variant was V600E). Brisk tumor-infiltrating lymphocytes were significantly more frequent in BRAF wild-type tumors compared with BRAF-mutant tumors. When assessing associations with survival, BRAF mutation status was not found to be an independent predictor. In the multivariate Cox model, TIL status was associated with improved OS (HR 3.33, 95% CI 1.41–7.88, p = 0.006). In addition, in the multivariate analysis, TIL status was also associated with improved PFS (HR 5.23, 95% CI 2.22–12.3, p < 0.001). BRAF wild-type tumors were significantly more likely to exhibit a brisk infiltrate. BRAF mutation status was not found to be an independent predictor of survival. TIL status remained significantly associated with OS and PFS in multivariable analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafMelanomaMutationSkin NeoplasmsHumansFemaleNeoplasm StagingMiddle AgedMaleAgedLymphocytes, Tumor-InfiltratingAdultPrognosis

Stichwörter der Autor:innen

BRAF mutationhistopathologymalignant melanomaprognosistumor infiltrating lymphocytes

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Department of Oncological Surgery and Gynecological Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Department of Surgical Oncology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, 400015 Cluj-Napoca, Romania.
  • Department of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
  • Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Department of Quality Management, "Prof. Dr. Ion Chiricuță" Institute of Oncology, 400015 Cluj-Napoca, Romania.
  • Department of Plastic Surgery, "Prof. Dr. Ion Chiricuță" Institute of Oncology, 400015 Cluj-Napoca, Romania.

ORCID-Profile: Vlad Alexandru Gâta, Daniel Corneliu Leucuța, Ștefan Țîțu, Ana Maria Mureșan-Bădescu, Ioan Constantin Pop, Alex Victor Orădan, Anda Gâta

Förderung

  • Iuliu Hațieganu University of Medicine and Pharmacy
  • “Iuliu Hațieganu” University of Medicine and Pharmacy Cluj-Napoca

Zitieren

APA

Gâta, V. A., Leucuța, D. C., Ilieș, R. A., Țîțu, Ș., Mureșan-Bădescu, A. M., Nicoară, D., Pop, I. C., Orădan, A. V., Muntean, M. V., & Gâta, A. (2026). Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II–III Malignant Melanoma. International Journal of Molecular Sciences, 27(14), 6150. https://doi.org/10.3390/ijms27146150

Vancouver

Gâta VA, Leucuța DC, Ilieș RA, Țîțu Ș, Mureșan-Bădescu AM, Nicoară D, et al. Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II–III Malignant Melanoma. International Journal of Molecular Sciences. 2026;27(14):6150. doi:10.3390/ijms27146150

BibTeX
@article{Gta2026,
  author = {Gâta, Vlad Alexandru and Leucuța, Daniel Corneliu and Ilieș, Radu Alexandru and Țîțu, Ștefan and Mureșan-Bădescu, Ana Maria and Nicoară, Delia and Pop, Ioan Constantin and Orădan, Alex Victor and Muntean, Maximilian Vlad and Gâta, Anda},
  title = {Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II–III Malignant Melanoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6150},
  doi = {10.3390/ijms27146150}
}
Kostenlos starten →